Pramiracetam Powder: molecular data, studies & sources

Pramiracetam Powder is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.

Compiled by PeptideTech Editors · Sources checked 2026-09-21 · Selected bibliography, not a systematic review

Molecular formula, weight & structure

Molecular formula (MF): C14H27N3O2
Molecular weight (MW): 269.38 g/mol
PubChem compound ID: 51712
Record title: Pramiracetam

Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.

Source: PubChem CID 51712 · retrieved 2026-09-21

PubChem 2D molecular structure for Pramiracetam Powder, CID 51712 — 2D depiction from PubChem. Open to inspect the full image. This drawing represents the selected record, not a vendor batch test.

Chemical identifiers and source data

IUPAC name: N-[2-[di(propan-2-yl)amino]ethyl]-2-(2-oxopyrrolidin-1-yl)acetamide
InChIKey: ZULJGOSFKWFVRX-UHFFFAOYSA-N
SMILES: CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C

Machine-readable PubChem source

Human and clinical studies

Selected human-study records are shown with their indexed or reviewed study type. Check the original article for the intervention, formulation and controls; the molecule can also be a comparator or measured variable.

Human study · PubMed trial index
Pharmacokinetics of oral pramiracetam in normal volunteers.
Chang T, Young RM, Goulet JR et al. · Journal of clinical pharmacology · 1985
PMID 4008675 · DOI: 10.1002/j.1552-4604.1985.tb02841.x
Human study · PubMed trial index
Placebo-controlled study of pramiracetam in young males with memory and cognitive problems resulting from head injury and anoxia.
McLean A, Cardenas DD, Burgess D et al. · Brain injury · 1991
PMID 1786500 · DOI: 10.3109/02699059109008110
Human study · PubMed trial index
Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam.
Claus JJ, Ludwig C, Mohr E et al. · Neurology · 1991
PMID 2011259 · DOI: 10.1212/wnl.41.4.570

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

Preclinical / laboratory research
[Pharmacokinetics of pramiracetam in animals].
Fang Z, Liu X, Xiao Y et al. · Hua xi yi ke da xue xue bao = Journal of West China University of Medical Sciences = Huaxi yike daxue xuebao · 1999
PMID 11387954

Pramiracetam Powder supplier sources

Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

Compare all Pramiracetam Powder sizes, forms and supplier prices →

Supplier	Recorded packages	Example source listing
Amino USAUSD	10000mg Powder1 recorded offers	10000mg Powder · $27.00Checked Sep 16, 2026Supplier listing

Reference sources & further reading

PubChem compound record 51712 — chemical identity and structure.
Wikipedia: Pramiracetam — Background encyclopedia; not a primary clinical source.

The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

Search for additional research

These links run searches; their results have not been individually reviewed and can include unrelated compounds.

Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.